Research statistics
Orforglipron research: publications and trials
At a glance
Publications, all years
125
Since 2020
Publications in 2026 so far
73
Through November 8, 2026
Human clinical research
24.2%
30 of 124 classified
Registered clinical trials
53
ClinicalTrials.gov
Randomized controlled trials
22
Publications reporting an RCT in people
Systematic reviews and meta-analyses
25
Preclinical studies
6.5%
4 animal · 2 in vitro · 2 computational
Records that only mention it
31
Not counted above
Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 1 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
- Not a peptide: it is shown for completeness and left out of every peptide total.
Publications by year
Orforglipron publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2020 | 0 | 1 | 0 | 0 | 1 |
| 2023 | 5 | 0 | 1 | 6 | 12 |
| 2024 | 1 | 1 | 10 | 0 | 12 |
| 2025 | 8 | 0 | 12 | 7 | 27 |
| 2026 (to date) | 16 | 6 | 35 | 16 | 73 |
Study types
| Review | 33 |
|---|---|
| Editorial, letter or other | 28 |
| Randomized controlled trial | 22 |
| Systematic review | 13 |
| Meta-analysis | 12 |
| Other clinical trial | 6 |
| Animal study | 4 |
| Computational study | 2 |
| In vitro study | 2 |
| Observational human study | 2 |
| Not yet classified | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 91 |
|---|---|
| Obesity and weight management | 71 |
| Endocrinology | 51 |
| Cardiovascular | 17 |
| Gastrointestinal | 9 |
| Neurological and mental health | 4 |
| Longevity and aging | 1 |
| Musculoskeletal | 1 |
| Reproductive and sexual health | 1 |
Registered clinical trials
1 of 29 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 33 · Recruiting: 9 · Active, not recruiting: 8 · Not yet recruiting: 3
Phase 1: 22 · Phase 2: 2 · Phase 3: 27 · Phase 4: 2
The 50 most recently started of 53 trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.
BMC endocrine disorders · September 15, 2026 · Meta-analysis · cited 0 times · open access
PMID 42750018 · DOI 10.1186/s12902-026-02538-x · Reviews and meta-analyses
- Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · July 15, 2026 · Meta-analysis · cited 1 times
PMID 42458197 · DOI 10.1007/s40292-026-00814-4 · Reviews and meta-analyses
- Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
Diabetes, obesity & metabolism · June 1, 2026 · Meta-analysis · cited 3 times · open access
PMID 42225305 · DOI 10.1111/dom.70919 · Reviews and meta-analyses
- Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.
Diabetes technology & therapeutics · February 4, 2026 · Meta-analysis · cited 3 times
PMID 41640110 · DOI 10.1177/15209156261420404 · Reviews and meta-analyses
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
Acta diabetologica · January 7, 2026 · Meta-analysis · cited 3 times
PMID 41498807 · DOI 10.1007/s00592-025-02635-8 · Reviews and meta-analyses
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
Frontiers in endocrinology · December 10, 2025 · Meta-analysis · cited 3 times · open access
PMID 41450584 · DOI 10.3389/fendo.2025.1646956 · Reviews and meta-analyses
- Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.
Medicine · December 1, 2025 · Meta-analysis · cited 5 times · open access
PMID 41465949 · DOI 10.1097/md.0000000000046671 · Reviews and meta-analyses
- Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism · November 1, 2025 · Meta-analysis · cited 9 times · open access
PMID 41296780 · DOI 10.1002/edm2.70134 · Reviews and meta-analyses
- Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
Diabetes technology & therapeutics · February 6, 2025 · Meta-analysis · cited 10 times
PMID 39911047 · DOI 10.1089/dia.2024.0533 · Reviews and meta-analyses
- Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.
Obesity pillars · January 30, 2025 · Meta-analysis · cited 32 times · open access
PMID 39980735 · DOI 10.1016/j.obpill.2025.100162 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
The New England journal of medicine · June 23, 2023 · Randomized controlled trial · cited 473 times
PMID 37351564 · DOI 10.1056/nejmoa2302392 · Human clinical research
- Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Proceedings of the National Academy of Sciences of the United States of America · November 11, 2020 · In vitro study · cited 225 times · open access
PMID 33177239 · DOI 10.1073/pnas.2014879117 · In vitro studies
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Lancet (London, England) · June 24, 2023 · Randomized controlled trial · cited 183 times
PMID 37369232 · DOI 10.1016/s0140-6736(23)01302-8 · Human clinical research
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
The New England journal of medicine · September 16, 2025 · Randomized controlled trial · cited 180 times
PMID 40960239 · DOI 10.1056/nejmoa2511774 · Human clinical research
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
The New England journal of medicine · June 21, 2025 · Randomized controlled trial · cited 127 times
PMID 40544435 · DOI 10.1056/nejmoa2505669 · Human clinical research
Latest publications
- [New oral anti-obesity drugs: the future or second choice?]
Innere Medizin (Heidelberg, Germany) · November 3, 2026 · Review · cited 0 times
PMID 42977781 · DOI 10.1007/s00108-026-02204-3 · Reviews and meta-analyses
- In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than dapagliflozin at 40 wk.
Annals of internal medicine · November 3, 2026 · Not yet classified · cited 0 times
PMID 42970798 · DOI 10.7326/annals-26-04099-jc · Not yet classified
- Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
The lancet. Diabetes & endocrinology · October 30, 2026 · Randomized controlled trial · cited 0 times
PMID 42962687 · DOI 10.1016/s2213-8587(26)00232-9 · Human clinical research
- Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment.
JAMA · October 26, 2026 · Editorial, letter or other · cited 0 times
PMID 42931747 · DOI 10.1001/jama.2026.18104 · Commentary and other
- Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.
JAMA · October 26, 2026 · Editorial, letter or other · cited 0 times
PMID 42931748 · DOI 10.1001/jama.2026.18107 · Commentary and other
- Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.
Omics : a journal of integrative biology · October 20, 2026 · Computational study · cited 0 times
PMID 42902597 · DOI 10.1177/15578100261499499 · Computational studies
- Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.
The patient · October 16, 2026 · Observational human study · cited 0 times · open access
PMID 42888373 · DOI 10.1007/s40271-026-00847-w · Human clinical research
- Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m<sup>2</sup> and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.
Obesity pillars · October 14, 2026 · Other clinical trial · cited 0 times
PMID 42936354 · DOI 10.1016/j.obpill.2026.100346 · Human clinical research
- Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.
Drug design, development and therapy · October 9, 2026 · Review · cited 0 times · open access
PMID 42871841 · DOI 10.2147/dddt.s637685 · Reviews and meta-analyses
- Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes.
Lancet (London, England) · October 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42880294 · DOI 10.1016/s0140-6736(26)02045-3 · Commentary and other
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Foundayo; LY3502970; Orforglipron
((TITLE_ABS:"Foundayo" OR CHEM:"Foundayo") OR (TITLE_ABS:"LY3502970" OR CHEM:"LY3502970" OR TITLE_ABS:"LY 3502970" OR CHEM:"LY 3502970") OR (TITLE_ABS:"Orforglipron" OR CHEM:"Orforglipron")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 9). Orforglipron research statistics (Version weekly-2026-11-08) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/orforglipron